9th Annual Biomarkers Congress
The 2nd World Congress on Controversies in the Management of Viral Hepatitis (C-Hep


Berlin, Germany
http://comtecmed.com/chep/2012/
Following the success of the 1st World Congress on Controversies in the Management of Viral Hepatitis (C-Hep), we are very pleased to invite you to participate in the 2nd C-Hep Congress which will be held in Berlin, Germany on October 18-20, 2012.

Schedule of Presentations:

Thursday, October 18, 2012
14:00:00 PLENARY SESSION 1 | HALL A Jürgen Rockstroh, Jonathan M. Schapiro
14:05:00 Chairpersons Congress Welcome Address
14:10:00 HCV in 2020: Any cases left? Rafael Esteban
14:30:00 Discussion
14:35:00 HCV vaccine: Where do we stand? Ulrich Spengler
15:00:00 Discussion
15:05:00 Interferon-free HCV therapy: Are we getting there? | No Graham Foster
15:25:00 Interferon-free HCV therapy: Are we getting there? | Yes Heiner Wedemeyer
15:45:00 Discussion
16:00:00 Pipeline Showcase: New Drugs on the Horizon
17:30:00 Coffee Break and Poster Exhibition
18:00:00 Janssen Satellite Symposium | DAAs: Raising Standards in Patient Care | HALL A
18:05:00 Welcome and introduction Thomas Berg
18:10:00 Practical recommendations in the era of DAAs
18:25:00 Managing DAA treatment in HIV-HCV co-infected patients Massimo Puoti
18:45:00 Understanding our patients: challenging clinical cases
19:05:00 Summary and key learnings Thomas Berg
19:15:00 Welcome Reception
19:30:00 Poster Prize Ceremony
Friday, October 19, 2012
09:00:00 PLENARY SESSION 2 | HALL A Eckart Schott, Stefan Zeuzem
09:05:00 Overview of HCV sessions by HCV Program Director Stefan Zeuzem
09:10:00 Direct Antivirals: How have the treatment paradigms changed?
09:15:00 Moderators Introduction
09:20:00 In treatment naïve Stanislas Pol
09:30:00 In treatment experienced Thomas Berg
09:50:00 Toxicity management Christoph Hezode
10:10:00 Drug-drug interactions David Back
10:40:00 Panel discussion
11:00:00 Coffee Break
11:30:00 SESSION 4: HCV therapy is for specialists only? (parallel session) | Yes | HALL B Marion G. Peters
11:30:00 SESSION 3: Do we need to know genetic factors such as IL28B for treatment decision making? (parallel session) | Yes | HALL A Vincente Soriano
11:45:00 SESSION 3: Do we need to know genetic factors such as IL28B for treatment decision making? (parallel session) | No| HALL A Matthew Albert
11:45:00 SESSION 4: HCV therapy is for specialists only? (parallel session) | No | HALL B Michael Biermer
12:00:00 Discussion | HALL B
12:00:00 Discussion
12:15:00 Lunch Break
13:00:00 Merck Sharp & Dohme Satellite Symposium Successful HCV Treatment in the Real World: Lessons From Clinical Practice | HALL A Jürgen Rockstroh
13:05:00 Welcome and Opening Remarks Jürgen Rockstroh
13:10:00 Emerging Evidence Guiding Clinical Practice Christoph Sarrazin
13:20:00 Optimizing Outcomes with Protease Inhibitors: Adverse Events Management and Prevention of Resistance Jean Michel Pawlotsky
13:40:00 Protease Inhibitors in Practice:Case Studies Geoffrey Dusheiko
14:00:00 Panel Discussion
14:10:00 Closing Remarks Jürgen Rockstroh
14:15:00 PLENARY SESSION 5 | HALL A
14:20:00 Fatty liver disease: what do we know? Claus Niederau
14:35:00 Vitamin D and liver disease: Which role does it play? Christian M. Lange
14:55:00 End-stage liver disease: What is new? Marion G. Peters
15:15:00 Treatment of HCC: state of the Art Massimo Puoti
15:35:00 Panel Discussion
15:45:00 Coffee Break
16:00:00 SESSION 7 (parallel session) | HALL B
16:10:00 SESSION 6 (parallel session) | HALL A
16:15:00 Patients should wait for DAA combination therapy | Yes | HALL A Patrick Ingiliz
16:15:00 Resistance to HCV Protease Inhibitors: Game over? | Yes | HALL B Jean Michel Pawlotsky
16:30:00 Resistance to HCV Protease Inhibitors: Game over? | Yes | HALL B Christoph Sarrazin
16:30:00 Patients should wait for DAA combination therapy | No | HALL A Geoffrey Dusheiko
16:45:00 Discussion | HALL A
16:45:00 Discussion | HALL B
17:00:00 SESSION 8 (parallel session) | Interactive Case Session | HALL A
17:00:00 SESSION 9 (parallel session) | Interactive Case Session | HALL B
17:05:00 Case discussion: How to treat HCV in HIV coinfection | HALL B Stefan Mauss
17:05:00 Case discussion: How to treat HCV relapse after OLTX | HALL A Raffaele Bruno
Saturday, October 20, 2012
08:30:00 PLENARY SESSION 10: HBV THERAPY IN 2012 | HALL A Jörg Petersen, Fabien Zoulim
08:35:00 Overview of HBV sessions by HBV Program Director Fabien Zoulim
08:40:00 Hepatitis B Therapy: State of the Art and open challenges Jörg Petersen
09:00:00 Is there a need for combination therapy? | Yes Florian van Boemmel
09:15:00 Is there a need for combination therapy? | No Maria Buti
09:30:00 HBV preventive and therapeutic vaccines: What is new? Marie-Louise Michel
09:50:00 Hepatitis Delta: What is new? Heiner Wedemeyer
10:10:00 Panel Discussion
10:30:00 Coffee Break
11:00:00 PLENARY SESSION 11: Interactive Case Session | HALL A Karine Lacombe, Mark Nelson, Fabien Zoulim
11:45:00 PLENARY SESSION 12 | HALL A
11:50:00 Strategies to prevent HCC: What can we do? Mark R. Thursz
12:00:00 Can we afford HCV DAAs for all? Maud Lemoine
12:15:00 What are the remaining challenges in hepatitis research? Michael P. Manns
4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.